California, Tel Aviv Firms to Jointly Develop Cannabis-Based Therapies

Therapix Biosciences of Tel Aviv, a specialty clinical-stage pharmaceutical company developing cannabinoid-based drugs, last week signed a memorandum of understanding with California-based CURE Pharmaceutical to enter into a research collaboration with Israel’s Assuta Medical Centers.

The two biopharma companies will jointly advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. Assuta will support the early research and development of potential projects at its eight hospitals and medical centers.

Robert Davidson, CEO of CURE Pharmaceutical, noted that Israel “is at the forefront of cannabinoid-based research in the world” and therefore is “the perfect place to start the development of these products.”

“As CURE focuses on targeting unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options, we are continuously looking to help bring new therapeutic cannabinoid-based products to market and further efforts toward the creation of personalized medicine,” Davidson said.

Therapix Biosciences’

... read more at:

Leave a Reply

Your email address will not be published. Required fields are marked *